Skip to content
Calculator
Evidence: HighPeptide conjugateFDA ApprovedRadiolabelled peptideFDA-approved 2016 · NetspotPET imaging

Gallium Ga 68 dotatate

A radiolabelled peptide that maps neuroendocrine tumours

Gallium Ga 68 dotatate is the somatostatin analogue octreotate, linked to a DOTA chelator and loaded with radioactive gallium-68. Injected before a PET scan, it binds the somatostatin receptors on most neuroendocrine tumours and shows where they are. FDA approved the Netspot kit in 2016.

Manufacturer's recommended dosing (FDA label): 2 MBq/kg (0.054 mCi/kg), maximum 200 MBq (5.4 mCi), Single injection, Intravenous bolus Details ↓

Overview

What is it?

Most well-differentiated neuroendocrine tumours carry many somatostatin receptors, especially subtype 2. Octreotate, a stable analogue of the hormone somatostatin, binds them tightly, and attaching a radioactive label turns it into a way of seeing the tumours. Gallium-68 is a positron emitter with a 68-minute half-life, so the scan is done soon after injection.

Gallium-68 PET largely replaced the older indium-111 pentetreotide scans, and the margin is large. A meta-analysis of ten studies found pooled per-patient sensitivity of 96% and specificity of 100%. In a prospective NIH study of 131 patients, it detected 95% of lesions against 45% on CT or MRI and 31% on indium-111 SPECT/CT, and changed management in a third. A 2016 systematic review also found it more sensitive than indium-111 octreotide in same-patient comparisons, with rare reports of harm.

Its value goes beyond finding a tumour. In a prospective Toronto registry of 482 newly diagnosed patients, the scan moved about one in five gut and pancreatic tumours to a higher stage, often by finding spread outside the liver, though it added less for tumours elsewhere in the body. At the NIH, the total volume of tumour lighting up on the scan predicted who would progress or die of the disease. In one survey of referring physicians, it led to intended management changes in 60% of 88 patients.

The same peptide carrying lutetium-177 treats these tumours, so the scan also selects patients for that therapy. Readers agree well on whether a scan is positive but less on who is suitable for treatment (kappa 0.80 against 0.64). Patients on lanreotide do not need to stop it beforehand: tumour uptake slightly increased after an injection.

It finds other receptor-bearing tumours too: the tumours that cause ectopic ACTH syndrome, phaeochromocytomas and paragangliomas, where it found every head and neck paraganglioma in one series, and meningiomas, where it is being used to plan radiotherapy. Those are research or off-label uses.

The label recommends 2 MBq/kg up to 200 MBq as an intravenous bolus, with plenty of water and frequent voiding to reduce radiation dose; it is approved for adults and children. It warns of radiation risk, hypersensitivity reactions and image misinterpretation, because uptake also occurs in other conditions.

95% vs 31%
Lesions detected, vs indium-111 SPECT/CT
NIH, 131 patients · PMID 26712231
2 MBq/kg
Labelled activity, up to 200 MBq
Netspot label 2.2
68 min
Gallium-68 physical half-life
Netspot label
Science

Mechanism of Action

Gallium-68 dotatate carries a positron emitter to somatostatin receptors, so receptor-rich neuroendocrine tumours show on a PET scan.

🎯

Somatostatin receptor 2

Distributes to SSTR2-expressing organs and tumours: pituitary, thyroid, spleen, adrenals, kidneys, pancreas and liver (Netspot label 12.3).

📡

Positron imaging

Gallium-68 decays with a 68-minute half-life, so imaging follows soon after injection (label).

🚰

Kidney clearance

About 12% of the dose is in the urine within four hours (label 12.3).

Evidence

Published Research

Studies of gallium-68 dotatate, from their PubMed abstracts.

Human2013

Diagnostic accuracy meta-analysis

Across ten studies of 416 patients, pooled per-patient sensitivity was 96% and specificity 100% for gallium-68 DOTATATE PET (93% and 85% for DOTATOC), with an area under the curve of 0.98.

PMID: 23928010
Human2016

Against indium-111 octreotide and conventional imaging

A systematic review of 42 eligible studies found gallium-68 DOTATATE more sensitive than indium-111 octreotide in same-patient comparisons, with estimated sensitivity 90.9% and specificity 90.6% against conventional imaging; possible harms were rare (6 of 974) and no major toxicity was reported.

PMID: 26769864
Human2015

Effect on management: referring physicians' view

In 88 patients, referring physicians reported intended management changes after gallium-68 DOTATATE PET/CT in 60%; 23% scheduled for chemotherapy were switched to treatments without chemotherapy.

PMID: 25500825
Human2025

Ectopic ACTH syndrome

In a prospective study of tumours causing ectopic ACTH syndrome, gallium-68 DOTATATE PET had a sensitivity of 79%, overlapping 18F-DOPA PET (88%) and far above octreotide scanning (31%).

PMID: 40036831
Human2025

Staging at diagnosis: a 482-patient registry

Adding somatostatin-receptor PET to conventional imaging changed the metastasis stage in 23.5% of patients; it upstaged 21.1% of gastroenteropancreatic tumours and found disease outside the liver in 36.8% of those thought to have liver-only spread, but upstaged only 9.6% of other tumours.

PMID: 39941805
Human2018

Tumour volume on the scan predicts outcome

In a prospective NIH study of 184 patients, larger gallium-68 dotatate-avid tumour volume tracked with shorter progression-free and disease-specific survival; 35.8 mL or more carried a hazard ratio of 10.6 for disease-specific death in multivariable analysis.

PMID: 29155309
Human2016

NIH prospective study, 131 patients

In 131 patients with gut and pancreatic neuroendocrine tumours or unexplained symptoms, gallium-68 dotatate PET/CT detected 95.1% of lesions against 45.3% on CT or MRI and 30.9% on indium-111 pentetreotide SPECT/CT, found an unknown primary in 4 of 14, and changed management in 32.8%.

PMID: 26712231
Human2022

Against indium-111 octreotide, prospectively

In 41 patients scanned with both, the PET found more lesions, mostly in liver and bowel, and changed management in 12.2%; it also turned up three unrelated findings, including a thyroid cancer and a lymphoma.

PMID: 35210659
Human2019

No need to stop lanreotide

In 31 patients scanned before and after a lanreotide injection, tumour uptake rose slightly while liver, spleen and thyroid uptake fell, so stopping long-acting somatostatin analogues before the scan was judged unnecessary.

PMID: 30097670
Human2016

Phaeochromocytoma and paraganglioma

In 30 patients, patient-level sensitivity was 93% for gallium-68 dotatate, 97% for fluorine-18 DOPA and 93% for conventional imaging; it found all 30 head and neck paragangliomas but missed two tiny phaeochromocytomas and one large recurrent one.

PMID: 26637204
Human2017

Do readers agree?

Across 50 patients read by several observers, agreement was substantial for whether the scan was positive (kappa 0.80), but lower for deciding who was suitable for radionuclide therapy (kappa 0.64).

PMID: 27539839
Human2024

Meningioma radiotherapy planning

In a 60-patient registry, scans were incorporated into meningioma radiotherapy planning; five patients with no uptake in the surgical bed were observed and none recurred over a median 19.5 months. Meningioma is not a labelled use.

PMID: 37871886
Dosing

Dosing Data

Netspot is a single intravenous diagnostic dose, prepared from a kit and calculated by body weight, given in a nuclear medicine department.

Radioactive diagnostic agent given only by nuclear medicine staff; drink water before and after and void frequently.
ProtocolDoseFrequencyDurationRoute
Label: PET localisation of somatostatin receptor-positive neuroendocrine tumours, adults and children Approved labelNetspot (kit for the preparation of gallium Ga 68 dotatate injection) US prescribing information (Novartis; DailyMed set b2b3be70, effective July 6, 2026)2 MBq/kg (0.054 mCi/kg), maximum 200 MBq (5.4 mCi)Single injectionOne scanIntravenous bolus

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Dosed by weight in becquerels
Netspot is 2 MBq per kilogram up to 200 MBq, measured in a dose calibrator by nuclear medicine staff; no reconstitution maths applies at home.
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

  • Netspot (68ga-dotatate kit): Vial 2 (buffer vial) containing 1 mL of reaction buffer solution. After radiolabeling with gallium-68 and pH adjustment with Reaction Buffer, Vial 1 contains a sterile solution of gallium Ga 68 dotatate at a strength up to 218 MBq/mL (5.89 mCi/mL). Forms the label lists: vials.

Source: Netspot (68ga-dotatate kit) label, section 3 (DailyMed version 23, effective July 6, 2026).

Mixing a vial: a worked example

Nothing to mix at home, and no syringe units to work out: Gallium Ga 68 dotatate is a radioactive drug, prepared and given in nuclear-medicine departments, and its dose is an amount of radioactivity (MBq or GBq), not a weight.

This page's dosing note: “Netspot is 2 MBq per kilogram up to 200 MBq, measured in a dose calibrator by nuclear medicine staff; no reconstitution maths applies at home.”

Its label says: “Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.”

Source: this page's own note in Dosing Data below; Netspot (68ga-dotatate kit) label, section 2 (DailyMed version 23, effective July 6, 2026); the amount of each dose row in Dosing Data below.

Storage before and after mixing

Before mixing or first use: “Storage and Handling For prolonged storage, store NETSPOT in its original packaging at room temperature below 25°C (77°F) (do not freeze).” “After radiolabeling with activities of up to 1,110 MBq (30 mCi), keep gallium Ga 68 dotatate injection upright with an appropriate shielding to protect from radiation, at a temperature below 25°C (77°F) (do not freeze), and use within 4 hours.” “The storage of the radiolabeled product must comply with regulatory requirements for radioactive materials.”

After mixing or first use: the label sentences we read say nothing separate about this.

Source: Netspot (68ga-dotatate kit) label, sections 16 and 2 (DailyMed version 23, effective July 6, 2026).

How it is taken

As the approved label gives it: Intravenous bolus (Single injection; Label: PET localisation of somatostatin receptor-positive neuroendocrine tumours, adults and children).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of gallium-68 physical half-life 68 minutes. After about five half-lives almost none is left.

How long the doses were given: Label: PET localisation of somatostatin receptor-positive neuroendocrine tumours, adults and children: One scan.

When effects appear: unknown; no source on this page gives a time to effect for Gallium Ga 68 dotatate. Results reported in the studies are under Published Research.

Source: half-life: Netspot prescribing information, physical characteristics (DailyMed set b2b3be70, effective July 6, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: A diagnostic dose given once; imaging risks rather than drug effects dominate. Full list and cautions ↓

When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Gallium Ga 68 dotatate. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the studies above”).

Interactions

  • somatostatin analogues (octreotide, lanreotide): compete for the same receptors and may affect imaging; image just before the next long-acting analogue dose
  • high-dose glucocorticoids: repeated high doses before the scan may affect imaging

Every peptide's record, with its source: the interaction matrix.

Source: Advanced Accelerator Applications. NETSPOT (kit for gallium Ga 68 dotatate) US prescribing information, section 7. DailyMed version of July 6, 2026, read October 3, 2026.

Checking what you bought

Unknown: no published independent test of Gallium Ga 68 dotatate products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (Approved in the US as Netspot (kit for the preparation of gallium Ga 68 dotatate injection), NDA 208547, on June 1, 2016 (Drugs@FDA via openFDA and the Netspot label effective July 6, 2026, read October 3, 2026)). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● A diagnostic dose given once; imaging risks rather than drug effects dominate

Contraindications & Cautions

Warnings from the Netspot label (DailyMed, effective July 6, 2026).

● Radiation risk
● Hypersensitivity reactions
● Risk of image misinterpretation
Questions

Frequently Asked Questions

?What is a gallium-68 dotatate scan?

A PET scan after an injection of a radiolabelled somatostatin analogue that binds the receptors on most neuroendocrine tumours, showing where they are.

?How accurate is it?

A meta-analysis found pooled per-patient sensitivity of 96% and specificity of 100%, and a 2016 systematic review found it more sensitive than indium-111 octreotide in same-patient comparisons.

?How is it related to Lutathera?

Lutathera uses the same octreotate peptide carrying lutetium-177 to treat neuroendocrine tumours; the gallium scan shows whether the tumours have enough receptors for it.

?Do I need to stop octreotide or lanreotide before the scan?

Not for lanreotide, on current evidence: in 31 patients, tumour uptake slightly increased after an injection. Centres set their own timing rules, so follow the department's instructions.

?How much radiation is injected?

The label gives 2 MBq per kilogram of body weight, up to 200 MBq, with fluids and frequent voiding to lower the dose to the bladder.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): NETSPOT, NDA 208547 (June 1, 2016). Read October 3, 2026.
  2. [fda-pi] FDA. Netspot (kit for gallium Ga 68 dotatate) US prescribing information (DailyMed set b2b3be70-17d8-4093-896c-f1c54a2cf242, version 23, effective July 6, 2026). Read October 3, 2026.
  3. [pubmed] Yang J, et al. "Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis." Acta Radiol, 2014;55(4):389-98. PMID: 23928010.
  4. [pubmed] Deppen SA, et al. "68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis." J Nucl Med, 2016;57(6):872-8. PMID: 26769864.
  5. [pubmed] Herrmann K, et al. "Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective." J Nucl Med, 2015;56(1):70-5. PMID: 25500825.
  6. [pubmed] Elenius H, et al. "Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome." J Clin Endocrinol Metab, 2025;110(11):e3794-e3802. PMID: 40036831.
  7. [pubmed] Metser U, et al. "(68)Ga-DOTATATE PET/CT in the Initial Staging of Well-Differentiated Gastroenteropancreatic and Non-Gastroenteropancreatic Neuroendocrine Tumors: Results of a Prospective Registry." Cancers (Basel), 2025;17(3). PMID: 39941805.
  8. [pubmed] Tirosh A, et al. "Prognostic Utility of Total (68)Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors." Gastroenterology, 2018;154(4):998-1008.e1. PMID: 29155309.
  9. [pubmed] Sadowski SM, et al. "Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites." J Clin Oncol, 2016;34(6):588-96. PMID: 26712231.
  10. [pubmed] Cavicchioli M, et al. "(68)Ga-DOTATATE PET/CT versus (111)In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study." Radiol Bras, 2022;55(1):13-18. PMID: 35210659.
  11. [pubmed] Aalbersberg EA, et al. "Influence of lanreotide on uptake of (68)Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation." Eur J Nucl Med Mol Imaging, 2019;46(3):696-703. PMID: 30097670.
  12. [pubmed] Archier A, et al. "Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases." Eur J Nucl Med Mol Imaging, 2016;43(7):1248-57. PMID: 26637204.
  13. [pubmed] Fendler WP, et al. "68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients." J Nucl Med, 2017;58(2):307-311. PMID: 27539839.
  14. [pubmed] Perlow HK, et al. "A Prospective Registry Study of (68)Ga-DOTATATE PET/CT Incorporation Into Treatment Planning of Intracranial Meningiomas." Int J Radiat Oncol Biol Phys, 2024;118(4):979-985. PMID: 37871886.
  15. [fda-pi] Netspot (kit for the preparation of gallium Ga 68 dotatate injection) US prescribing information (Novartis; DailyMed set b2b3be70, version 23, effective July 6, 2026), sections 2.1, 2.2 and 12.3; read through openFDA October 6, 2026.

Sources & Citations

Studies were read from their PubMed abstracts; the Netspot label from DailyMed (set b2b3be70, effective July 6, 2026) through openFDA, read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-03